Y.D. More Investments Ltd decreased its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 10.9% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 301,734 shares of the company's stock after selling 37,016 shares during the period. Y.D. More Investments Ltd owned approximately 0.15% of Cellebrite DI worth $6,647,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of CLBT. Calamos Advisors LLC increased its holdings in Cellebrite DI by 198.3% in the 4th quarter. Calamos Advisors LLC now owns 106,979 shares of the company's stock valued at $2,357,000 after purchasing an additional 71,120 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Cellebrite DI in the fourth quarter valued at about $100,000. Blue Trust Inc. acquired a new position in Cellebrite DI during the 4th quarter worth approximately $466,000. Juncture Wealth Strategies LLC grew its position in Cellebrite DI by 0.8% in the fourth quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company's stock valued at $1,322,000 after acquiring an additional 505 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its position in shares of Cellebrite DI by 30.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 66,487 shares of the company's stock worth $1,465,000 after purchasing an additional 15,332 shares in the last quarter. 45.88% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
CLBT has been the subject of a number of analyst reports. Craig Hallum upped their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their target price on Cellebrite DI from $22.00 to $24.00 and gave the company an "overweight" rating in a research report on Monday, December 16th. Finally, Needham & Company LLC raised their price target on shares of Cellebrite DI from $21.00 to $28.00 and gave the stock a "buy" rating in a research report on Wednesday, January 22nd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $21.57.
View Our Latest Report on CLBT
Cellebrite DI Price Performance
Shares of CLBT stock traded up $0.20 on Friday, hitting $25.41. 2,173,997 shares of the stock traded hands, compared to its average volume of 1,762,856. The company has a market capitalization of $5.23 billion, a PE ratio of -16.39, a PEG ratio of 3.72 and a beta of 1.47. The company's fifty day moving average is $22.31 and its 200 day moving average is $18.81. Cellebrite DI Ltd. has a 1-year low of $8.91 and a 1-year high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. The business had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The company's quarterly revenue was up 27.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.09 EPS. As a group, equities research analysts expect that Cellebrite DI Ltd. will post 0.32 EPS for the current year.
Cellebrite DI Company Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
